Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Royalty Pharma plc (RPRX)

Royalty Pharma enters $1.8 billion unsecured revolving credit facility maturing 2031

Neutral Impact 3 of 5 financing Written later

On May 22, 2026, Royalty Pharma signed a new $1.8 billion unsecured revolving credit agreement with Bank of America, N.A. as administrative agent, replacing its September 15, 2021 facility in full. The new facility matures May 22, 2031, and the filing lists financial covenants that shareholders can track.

Key points

  • Facility size is $1.8 billion, unsecured, with Bank of America, N.A. as administrative agent
  • Replaces the Existing Credit Agreement dated September 15, 2021; all obligations under it were repaid and its commitments terminated
  • Maturity date is May 22, 2031
  • Covenants require a consolidated leverage ratio at or below 4.00 to 1.00 and a coverage ratio of at least 2.50 to 1.00

The filing

CompanyRoyalty Pharma plc (RPRX)
Form8-K, current report
Filed with the SECMay 28, 2026, 4:01 PM ET
Accession number0001193125-26-245163

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.